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The immunodominance of a major antigenic site of foot-and-mouth disease virus (FMDV) (serotype C; clone C-S8cl) in 
a natural host has been evaluated by serum immunoglobulin fractionation. Nineteen sera from either convalescent or 
vaccinated swine were fractionated by affinity chromatography using a synthetic peptide representing antigenic site A (the 
G-H loop of capsid protein VP1) coupled to a Sepharose matrix. Antigen-binding and neutralizing activities of serum fractions 
were quantitated. On average, about 57 or 27% of the virus-neutralizing activity (and about 35 or 12% of the virus-binding 
activity) from convalescent or vaccinated swine, respectively, corresponded to antibodies against site A. The results provide 
direct evidence of the important contribution of site A, and also of additional site~ unrelated to site A, in the evoking of 
neutralizing antibodies by FMDV in a natural host. The proportion of antibodies directed to site A varied greatly among 
individual swine. Some animals evoked remarkably ow levels of antibodies pecific for site A although they were competent 
to raise antibodies against other antigenic sites of FMDV. Thus, the major antigenic site of FMDV shows heterogeneous 
dominance in a natural host. Possible implications for evolution of viral quasispecies are discussed. © 1995 Academic 
Press, Inc. 
Foot-and-mouth disease virus (FMDV) is a picornavi- 
rus that causes an economically important disease of 
farm animals. The virus conforms to a quasispecies ge- 
netic structure in that FMDV populations consist of fluctu- 
ating distributions of genetic and antigenic variants (So- 
brino eta/.,  1983; Mateu et al., 1988, 1989; review in 
Domingo eta/., 1992). Seven distinct serotypes of FMDV 
(termed A, O, C, Asia1, SAT1, SAT2, and SAT3) have been 
characterized, and each serotype includes a large but 
indeterminate spectrum of subtypes and variants (Per- 
eira, 1977) which often cocirculate during disease out- 
breaks (Mateu eta/., 1988; Domingo eta/., 1992). This 
antigenic heterogeneity is one of the major obstacles to 
controlling FMD by vaccination. 
The interpretation of the mechanisms governing the 
antigenic diversification of highly variable viruses de- 
pends to a large extent on the identification of antigenic 
sites and on the evaluation of the selective pressures to 
which they may be subjected during virus replication. 
Several antigenic sites have been identified in FMDV 
(Thomas eta/., 1988a; Parry eta/., 1989; Baxt eta/., 1989; 
Mateu et aL, 1990; Kitson eta/., 1990; Lea et al., 1994). 
In serotype C (clone C-S8cl), three topologically and 
functionally independent antigenic sites have been char- 
acterized= (i) a major site (termed site A) is located within 
residues 138 to 150 at the disordered G-H loop (Acharya 
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etaL, 1989; Logan eta/., 1993; Lea eta/., 1994)of capsid 
protein VP1. Site A is composed of multiple, continuous 
epitopes (Mateu eta/., 1990) which include a highly con- 
served RGD motif also involved in cell receptor recogni- 
tion (Fox eta/., 1989; Mason etaL, 1994); (ii) the carboxy- 
terminus of VP1 (around residues 195 to 209) which con- 
stitutes in this serotype a minor, independent antigenic 
site termed site C (Mateu eta/., 1990); (iii) another major, 
complex site (termed site D) is composed of discontinu- 
ous epitopes involving residues of VP1, VP2, and VP3 
near the capsid threefold axis (Lea et a/., 1994). 
immune pressure to each individual antigenic site in 
a natural host will be partly determined by the degree of 
immunodominance of each site. In FMDV the immune- 
dominance of each antigenic site in the natural hosts 
has not been quantitated. Indirect evidence, obtained 
mainly with model laboratory animals or using MAbs, 
suggested that site A may be highly immunodominant. 
The specific removal of sites A and C by trypsin treatment 
of intact type O virions led to a substantial decrease in 
their immunogenicity and antigenicity (Wild and Brown, 
1967; Strohmaier et al., 1982). Also, variant peptides rep- 
resenting site A often mimicked the serotype, subtype, 
and strain specificities of entire particles (Bittle et at., 
1982; Rowlands eta/., 1983; Clarke et al., 1983; Mateu 
etaL, 1989, 1992). However, during the evolution of FMDV 
of serotype C in the field over the last six decades, vi- 
ruses with antigenically drastic replacements at site A 
have been rare and have never constituted significant 
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evolutionary sublines (Mart[nez et a/., 1991, 1992). This 
would not be expected if the virus were subjected to 
continuous and intense positive selection by antibodies 
directed to site A. Moreover, indirect evidence suggests 
that other antigenic sites identified in FMDV are also 
highly relevant to the antigenic diversification of the virus 
in the field (Thomas et al., 1988b; Feigelst0ck et aL, 1992; 
Mateu et el., 1994). 
In the present report we describe the fractionation of 
anti-FMDV (C-S8cl) serum antibodies from convalescent 
and from vaccinated swine with the aim of establishing, 
(i) the degree of immunodominance in a natural host of 
antigenic site A relative to other antigenic sites and (ii) 
the extent of variation in immunodominance of site A 
among individuals of a host species. The results reveal 
that site A behaves as a highly immunogenic domain in 
e natural host. However, a major fraction of antibodies, 
including neutralizing antibodies, are directed against 
other antigenic sites. Moreover, site A behaves as nearly 
immunosilent in some individual animals. 
MATERIALS AND METHODS 
Viruses 
FMDV C-S8cl is a plaque-purified derivative of isolate 
0-$8 (01 Santa Pau-Sp/70; described in Sobrino et aL, 
1983), the prototype type C vaccine strain used in Spain 
ever the last two decades. FMDV SD6-28 is a MAb-resis- 
tant (MAR) mutant of C-S8cl selected with neutralizing 
MAb SD6 (Mateu et aL, 1989, 1990). 
Synthetic peptides 
The peptides used in the present study are listed in 
Table 1. Their synthesis and reactivities with anti-FMDV 
MAbs have been described elsewhere (Mateu eta/. ,  
1989, 1990; CarreSo et aL, 1992). For antigen-competition 
ELISAthe peptides were used as free peptides; for immu- 
n0dot assays they were conjugated to keyhole limpet 
hemocyanin (KLH). 
M0noclonal antibodies 
The MAbs used were raised against FMDV type C; 
each MAb recognizes a different, continuous epitope 
within antigenic site A (Mateu et eL, 1990, and references 
therein). 
Animal sere 
Sera from FMDV-vaccinated and from FMD-convales- 
cent swine (outbred Landrace X Large White, three gen- 
erations in isolation, aged 5 to 8 weeks with no prior 
contact with FMDV; animals 861 and 863 were inbred 
miniature pigs) were provided by Laboratorios Sobrino 
(0lot, Girona, Spain) or, in a few cases, by Departamento 
de Sanidad Animal, I.N.I.A. (Madrid, Spain) (Table 2). To 
produce the sera, animals were either infected with 
TABLE 1 
SYNTHETIC PEPTIDES USED IN THE PRESENT STUDY 
Peptide 
designation a Sequence b 
A21 
A19 
C18 
C15 
p38 
YTASAR G DLAH Lq-lq-HARH LP(C) 
ASARG DLAH LFFrHAR H LP(C) 
PTG DR H KQPLVAPAKQ LL(C) 
DRHKQPLVAPAKQLL 
RH KQPLVAPAKQLL(PPS)- 
ASARG DLAH LqqTHARH LP(CG) 
Peptides A21, A19, and 018 were conjugated through a C-terminal 
Oys to keyhole limpet hemocyanin (KLH) and used in immunodot 
assays. Peptides A21, 015, and p38 were used as free peptides in 
antigen competition assays (see Materials and Methods). 
b Peptides A21 and A19 include antigenic site A (residues 138-150) 
of FMDV C-S8cl; peptides O18 and O15 include antigenic site 0 (resi- 
dues 195.to 209 of VP1). The sequence of peptide p38 includes the 
carboxy-terminal VP1 residues 196 to 209 linked by a PPS triplet to 
VP1 residues 138 to 156, followed by CG at its carboxy-end. This pep- 
tide includes antigenic sites A and C and is the counterpa r[ for serotype 
C of a peptide construct first described by Di Marchi et aL (1986) for 
FMDV of serotype O. Amino acids not present in the authentic 0-$8cl 
sequence are given in parentheses. 
FMDV C-S8cl or vaccinated with monovalent ype C (C- 
S8cl) inactivated virus vaccine administered according 
to official FMD vaccination procedures in Spain (Euro- 
pean Pharmacopeia). Briefly, FMDV was inactivated with 
bromoethylenimine, and the standard antigen dose [ap- 
proximately 10 s tissue culture infective dose 50 (TCID50), 
equivalent o 0.6 #g 140S particles] was emulsified with 
an oil adjuvant and inoculated intramuscularly into ani- 
mals. All animals were revaccinated at least once (Table 
2). Sera from convalescent swine were collected 16 to 
32 days after infection, and sera from vaccinated swine 
were collected 15 to 60 days after the last vaccine admin- 
istration. Some swine were vaccinated with synthetic 
peptide p38 (Table 1) which includes antigenic sites A 
and C of FMDV C-$8cl (Table 2). Preimmune and several 
control swine sera were also obtained and analyzed; 
they were negative in each of the immunoassays de- 
scribed here. The integrity of VP1 was tested by electro- 
phoretic analysis of each vaccine batch used. In experi- 
ment 6 (Table 2), the animals were challenged with infec- 
tious C-S8cl virus, following official procedures for the 
testing of commercial vaccines (administration of 104 
mice DL~o per animal; this virus dose caused generalized 
disease in at least 80% of nonimmune swine). 
Coupling of peptide to aminohexyl (AH)-Sepharose 
Five hundred milligrams of AH-Sepharose (Phar- 
macia, 20 ffmol amino groups) was washed with 0.5 M 
NaCI (five times with 10 ml/each), resuspended in 1 ml 
of 0.1 M sodium phosphate, pH 7.8, and derivatized by 
reaction with 20 mg (3 equivalents) of 3-maleimidoben- 
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TABLE 2 
SERA FROM SWINE INFECTED OR VACCINATED WITH FMDV C-S8c1 USED IN THE PRESENT STUDY 
Neutralization index ~ 
Experiment Days postinfection Reactivity ratio 
numbed Animal ~ or postvaccination c PRN50 TOLD50 (peptide A19/virus) e
Convalescent animals 
1 VFAC-1 32 3.95 ND 0.26 
VFAC-2 32 
2 827-1 22 3.72 ND 0.30 
827-2 22 
827-3 22 
3 175 16 4.34 ND 0.24 
176 16 4.05 ND 0.11 
4 726 23 4.20 ND 0.14 
727 23 3.64 ND 0.25 
Average 3.92 - -  0.24 
Vaccinated animals 
5 474 19 3.39 ND 0.15 
475 19 2.25 ND 0.05 
6 a 39 21 3.24 1.65 <0.02 
40 21 ND 1.50 0.22 
44 21 3.24 2.55 0.16 
48 21 ND 1.50 <0.20 ~ 
49 21 3.03 1,35 0.06 
7 13 60 4,28 2.40 0.41 
27 60 ND 1.80 0.59 
40a 60 ND 1.80 0.36 
53 60 4.20 2.25 0.12 
54 60 4.25 2.25 0.10 
55 60 ND 2.10 0.36 
56 60 ND 2.40 0.08 
57 60 ND 2,25 0.14 
8 861 15 3.70 ND 0.24 
863 15 3.76 ND 0,27 
Average 3.53 1.98 0.20 
6 a 51 (p38) 21 3.50 1,80 0.96 
a Each different experiment has been assigned a number; 1 to 4, animals infected with FMDV 0-88ol; 5 to 8, animals vaccinated with whole- 
virus-inactivated vaccine based on FMDV C-S8cl (described under Materials and Methods). Animal 51 belongs to experiment 6 but it was vaccinated 
with peptide p38 (last line; see Table 1 and Materials and Methods). 
Sera from animals VFAC-1 and VFAC-2 and sera from animals 827-1, 827-2, and 827-3 were provided as pooled sera (termed VFAO and 827, 
respectively, in the text); the values for the neutralization index and for the reactivity ratio peptide A19/virus correspond to those for the pooled 
sera. Accordingly, when average values were calculated, the values obtained with sera VFAC and 827 were given double and triple weight, 
respectively. Sera from nonimmunized animals or preimmune sera gave no detectable neutralization or binding to FMDV 0-$801 (data not shown). 
°This indicates the day after infection or after the last immunization at which serum was obtained. Infection and vaccination procedures are 
given under Materials and Methods. Animals from experiments 5, 7, and 8 were revaccinated 21 days after primovaccination; animals from experiment 
6 were revaccinated 29, 53, and 86 days after primovaccination. 
~The plaque-reduction neutralization 50 (PRNS0) titer is the log of the inverse of the serum dilution which causes a 50% reduction in the number 
of plaque-forming-units in the plaque-reduction neutralization assay described under Materials and Methods. The tissue culture infectious dose 50 
(TOLD50) titer is the log of the inverse of the serum dilution which allows cytopathology in 50% of wells with cells challenged with a standard dose 
of virus. This latter assay was performed in Laboratorios, Sobrino, S. A. (Clot, Girona, Spain) only with sera from vaccinated swine as part of routine 
assays in vaccine evaluations. ND, not determined. 
eThis ratio is the signal obtained with peptide A19 in EID assays relative to the signal obtained with an equivalent molar amount o[ the 
corresponding peptide segment in virus particles. Values are the average of two determinations. Similar results were obtained using peptide A21 
(results not shown). 
For this sample the ratio could not be determined accurately because of the low reactivity-- both with FMDV 0-S801 and with peptide A19 or 
A21 - -o f  serum 48 in the EID assay. This value was not considered in the calculation of the average reactivity ratio (last line). 
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zoic acid N-hydroxysuccinimide ster (Sigma) in 2 ml 
dimethylformamide (DMF) for 2 hr at room temperature. 
Excess reagent was removed by repeated washes with 
H20-DMF (1=1). This maleimido-activated support 
(MBAH-Sepharose) was then reacted overnight with 
peptide A21 (4/~mo!; Table 1 ) in 1 ml of phosphate buffer. 
Unreacted maleimido sites were capped by means of 
2-mercaptoethanol (50 #1 in 3 ml of buffer, 2 hr). The 
substitution of the affinity gel was determined by amino 
acid analysis; it ranged from 0.8 to 1.5 #mol peptide/ml. 
Swine immunoglobulin (Ig) fractionation 
Specific Ig in serum of convalescent or vaccinated 
swine at the time it was obtained was IgG, and all FMDV- 
specific swine IgG (as well as most of the IgM, when 
present) was retained in protein A-Sepharose. Thus, as 
a first step for the isolation of site A-specific antibodies, 
total Ig was purified by protein A-Sepharose affinity 
chromatography. This and subsequent steps were car- 
ried out at 4 °. Sera (1 to 2 ml) were clarified by centrifuga- 
ti0n (10 min at 10,000 g), diluted 1,1 with buffer A (1.5 M 
glycine, 3 M NaCI, pH 8.9), and applied to a protein 
A-Sepharose (Pharmacia) column (2.5 ml bed volume) 
previously equilibrated with buffer A. After washing the 
column, bound antibody was eluted with 0.1 M citrate 
buffer, pH 3, and the solution was immediately neutral- 
ized to pH 7. Ig was concentrated by precipitation with 
ammonium sulfate to 50% saturation, dissolved in 20 mM 
Tris-HCI, pH 7.7, and dialyzed against the same buffer. 
Antibodies specific for antigenic site A of FMDV were 
purified by affinity chromatography on the A21-MBAH- 
Sepharose column (described above), to which peptide 
A21 (which includes antigenic site A of FMDV C-SScl, 
Table 1) was coupled to the solid matrix through a C- 
terminal Oys residue. The column (0.7 ml bed volume, 
0.55 #mol peptide) was equilibrated with 20 mM Tris- 
HCI, pH 7.7, 0.5 M NaCl. Purified swine Ig (usually 10 to 
25 rag) was applied in the same buffer, and the column 
washed. Unbound Ig included nonspecific antibodies 
and anti-FMDV antibodies not directed to antigenic site 
A (see Results and Discussion). Antibodies directed to 
site A which bound to peptide A21 were eluted with 0.1 
Mglycine-HCI, pH 2.5, and the solution was immediately 
neutralized to pH 7. Further elution in 0.1 M glycine- 
NaOH, pH 11, 2 M urea, or 1 M LiCI did not yield signifi- 
cant amounts of protein. Unbound and eluted protein 
fractions were dialyzed against phosphate-buffered sa- 
line (PBS), concentrated by ultrafiltration in Centricon- 
30 (Amicon), and stored at -20 ° until used. Purified Ig 
concentration was determined by ultraviolet absorption 
at 280 nm (10D = 0.75 mg/ml of pure Ig), and in some 
cases also by SDS-PAGE and densitometry of the Coo- 
massie blue-stained gel using known amounts of protein 
as the standard. 
Enzyme immunodot and viral neutralization assays 
Immunodot assays were carried out essentially as de- 
scribed (Mateu et aL, 1987) with the following modifica- 
tions, saturation of the nitrocellulose sheet was in 5% 
BSA in PBS; 1.5 ml of each antibody solution was used; 
the washings were in 0.1% Tween 20 in PBS; either goat 
anti-mouse IgG-peroxidase conjugate (Bio-Rad, 1=1500 
dilution in PBS) or rabbit anti-pig IgG-peroxidase conju- 
gate (Sigma, 1=1000 dilution in 2% BSA in PBS) was em- 
ployed, depending on the first antibody. Amounts of anti- 
gen (usually 20 pmol) which did not saturate the nitrocel- 
lulose and nonsaturating amounts of anti-FMDV 
antibodies were used. Dots were quantitated in a Joyce- 
Loebl Chromoscan densitometer. Plaque-reduction neu- 
tralization assays were carried out in duplicate as de- 
scribed (Mateu et aL, 1987) using four 5- to 10-fold dilu- 
tions of each antibody fraction. 
RESU LTS 
Reactivity of swine sera with synthetic peptides 
A total of 26 sera from swine experimentally infected 
or vaccinated with FMDV (clone C-S8cl) have been ana- 
lyzed (Table 2). The sera were produced in eight indepen- 
dent experiments and exhibited high neutralization titers 
against C-SScl, well within the range generally associ- 
ated with protection against homologous FMDV infec- 
tion. In experiment 6 (Table 2), the animals were chal- 
lenged with FMDV C-SScl and, as expected, all vacci- 
nated swine--but none of the unvaccinated, control 
animals-- were protected. Protection was documented 
also for animal 51 (Table 2) and four additional animals 
(not listed in Table 2) which were vaccinated with peptide 
p38--a construct with antigenic sites A and C, listed 
in Table 1 (unpublished results). Neutralization titers in 
serum from convalescent animals were comparable to 
the titers in serum from vaccinated animals-  including 
those vaccinated with peptide p38 (Table 2 and results 
not shown). 
To test the immunodominance of antigenic site A, the 
reactivity of each serum was quantitated with synthetic 
peptides A21 and A19 (sequence given in Table 1) rela- 
tive to the reactivity with viral particles in immunodot 
assays (Table 2). The reactivity ratio (peptide A19/virus) 
ranged from 0.11 to 0.30 for convalescent and from less 
than 0.02 up to 0.59 for vaccinated swine; the mean val- 
ues were 0.24 and 0.20, respectively (Table 2). However, 
sera from vaccinated animals 475, 39, 49, 54, and 56 
reacted with virus but showed weak or undetectable re- 
activity with site A peptides (reactivity ratio peptide/virus 
~< 0.1). In experiment 6, animal 51 vaccinated with pep- 
tide p38 was included as a control. Serum from this ani- 
mal exhibited a reactivity ratio (peptide A19/virus) of 0.96 
(Table 2, last line), a large value which implies an immune 
response directed mainly to the site A moiety of the p38 
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antigen. The latter result was also observed with sera 
obtained from a number of additional pigs immunized 
with peptides p38 or A19 (data not shown). The above 
observations suggest that a significant proportion of the 
antibody response against the virus was directed to site 
A. They also suggest important variations among individ- 
ual animals regarding the proportion of site A-specific 
antibodies that they generate. 
Immunodominance of site A in a natural host 
To evaluate directly the degree of immunodominance 
of antigenic site A, we used peptide A21 conjugated to 
Sepharose (A21-MBAH-Sepharose) to fractionate the 
animal sera by immunoaffinity chromatography. Table 3 
summarizes results of binding and neutralization of 0- 
$8cl obtained with 19 fractionated sera. For any serum 
tested, the antibody fraction not retained byA21 -MBAH-  
Sepharose did not react with peptides A21, A19, C15, or 
p38 in immunoassays (Fig. 1, and data not shown). Thus, 
no significant amounts of site A-specific antibodies failed 
to bind to A21 -MBAH-Sepharose (see also below). The 
activities in the Ig fraction not retained (NR) in the A21- 
MBAH-Sepharose were compared with those of the 
fraction retained (R) in the peptide column. In agreement 
with the results of binding of sera to peptides A21 or 
A19 (Table 2), the proportion of both the binding and 
neutralization activities associated with the retained frac- 
tion varied from one animal to another, to an extent which 
could not be attributed to experimental error (see below). 
On average, 38 and 16% (35 and 12% when values were 
corrected for a small fraction of unspecific Ig retained 
on the column, see Table 3) of the total virus-binding 
activity recovered from convalescent and vaccinated ani- 
mals, respectively, were associated with the antibody 
fraction retained in the A21 -MBAH-Sepharose. The cor- 
responding values for neutralizing activity were 59 and 
30% (57 and 27%, corrected). Site A appeared as more 
immunodominant in convalescent than in vaccinated 
swine. Again, serum from animal 51 immunized with pep- 
tide p38 provided a good control in that, as expected, 
most peptide p38- or virus-binding activities, as well as 
all peptide A21-binding and all neutralizing activity of 
this serum, were retained bythe A21 -MBAH-Sepharose 
(Fig. 2 and Table 3). A minor fraction of specific, nonneu- 
tralizing antibodies present in serum 51 was generated 
against site C or against structures present in p38 but 
not represented in the A21 -MBAH-Sepharose construct 
(Table 3). The above results provide direct evidence of 
the important contribution of site A, but also of other 
antigenic sites unrelated to site A, in the eliciting of neu- 
tralizing antibodies of FMDV of serotype C in a natural 
host. 
Reactivity with MAR mutant SD6-28 
To further confirm that nearly all the antibodies not 
retained by A21 -MBAH-Sepharose were directed to an- 
tigenic sites other than site A we tested the neutralization 
of MAR mutant SD6-28 (Mateu et al., 1990) by the NR 
and RIg fractions. The capsid of this mutant differs from 
that of 0-$8cl in a single amino acid substitution within 
site A (H-146 -* R). This replacement greatly diminished 
binding and neutralization by each site A-specific MAb 
tested (Mateu et al., 1990; Martlnez et al., 1991 Carre~o 
et aL, 1992), and also by most guinea pig polyclonal 
antibodies elicited against a peptide which included site 
A (Borrego et al., 1993). For the R fraction of each of the 
sera analyzed, about 5- to 20-fold more antibody was 
needed to neutralize 50% of the plaque-forming units of 
SD6-28 relative to C-$8cl (given by the N ratio in Table 
3; see Fig. 1). In contrast, SD6-28 was neutralized to the 
same extent as 0-$8cl by the NR fraction of each of the 
sera analyzed (Fig. 1 and data not shown). These results 
again indicate that the immunoaffinity chromatography 
step effectively separated antibodies directed to site A 
from those directed to other antigenic sites on the virus. 
Variations in the immune response to site A among 
individual host animals 
Differences in the proportion of antibodies directed to 
site A among individual animals were in some cases 
remarkable (Table 3). This is reflected in the standard 
deviations of the average corrected values for convales- 
cent animals (35 _+ 12 and 57 + 24% for virus binding 
and neutralization activities, respectively, in the serum 
fractions retained in the A21-MBAH-Sepharose), and 
the corresponding values for vaccinated animals (12 _+ 
8 and 27 _+ 29%). For comparison, the average value for 
the virus-binding activity of the fraction retained in the 
A21 -MBAH-Sepharose upon four independent fraction- 
ations of the same serum (serum 13), was 18.5 + 3.1% 
(results not shown). Less than 6% of the C-S8cl-binding 
activity of sera from animals 39, 49, and 64 may corre- 
spond to site A antibodies (Table 3). Likewise, only 2 to 
11% of the total neutralizing activity recovered from sera 
of animals 726, 39, 49, 53, 54, and 863 is due to antibod- 
ies directed to site A (Table 3). Thus, some animals elic- 
ited a very low proportion of site A-specific antibodies. 
DISCUSSION 
The host immune response is one of the major selec- 
tive constraints effecting antigenic variation of viruses 
during their replication in the field. However, very few 
studies have directly measured a specific antibody re- 
sponse against individual antigenic sites of a virus, and 
possible variations in intensity among individual host ani- 
mals. Antigenic site A of FMDV offers several advantages 
to quantitate immunodominance. Site A of type C viruses 
is composed of continuous epitopes (Mateu et aL, 1989, 
1990) delineated by a single peptide segment (the G-H 
loop of VP1) displaying considerable structural flexibility 
(Acharya etaL, 1989; Parry eta/., 1990; Logan eta/., 1993; 
TABLE 3 
FRACTIONATION OF ANTI-FMDV ANTIBODIES PRESENT IN SERA FROM OONVALESCENT OR VACCINATED SWINE a 
Experiment 
number b
Total Ig Ig (%)~ 
conc. 
Animal b (mg/ml) ° NR R NR R 
C-S8cl-binding activity C-S8cl-neutralizing 
(%)e activity (%Y 
NR R N ratio ~ 
1 VFAC-1 22 
VFAC-2 
2 827-1 16 
827-2 
827-3 
3 175 12 
176 11 
4 726 7 
727 11 
Average 14.8 
Oonvalescent animals 
84 16 52 (55) 48 (46) 41 (43) 59 (57) 5 
89 11 61 (64) 39 (36) 19 (20) 81 (80) 6 
88 12 55 (58) 45 (42) 34 (36) 66 (64) 5 
86 14 79 (83) 21 (17) 58 (61) 42 (39) 7 
92 8 83 (87) 17 (13) 89 (93) 11 (7) ND 
91 9 59 (62) 41 (38) 46 (48) 54 (52) 3 
88 12 62 (65) 38 (35) 41 (43) 59 (57) 5 
8 
Average 
Vaccinated animals 
474 16 92 8 72 (76) 28 (24) 26 (26) 75 (74) 20 
475 10 90 10 80 (84) 20 (16) 14 (15) 86 (85) >18 
39 12 90 10 95 (100) 5 (0) 90 (95) 10 (5) 2 
44 13 89 11 81 (85) 19 (15) 66 (69) 34 (31) >6 
49 18 84 16 89 (94) 11 (6) 85 (89) 15 (11) 1 
13 16 91 9 77 (81) 23 (19) 71 (74) 29 (26) 10 
53 18 93 7 85 (90) 15 (10) 93 (98) 7 (2) 2 
54 17 95 5 95 (100) 5 (0) 92 (96) 8 (4) 1 
861 19 93 7 79 (83) 21 (17) 77 (81) 23 (19) >10 
863 15 93 7 84 (88) 16 (12) 85 (89) 15 (11) 18 
15.4 91 9 84 (88) 16 (12) 70 (73) 30 (27) >13 
Average (total) 15.1 90 10 74 (78) 26 (22) 56 (59) 44 (41) >9 
6 61(p38) 12 80 20 37 (39) 63 (61) 0 100 4 
~The average yield in the Ig purification of total serum by protein A-Sepharose chromatography followed by ammonium sulfate precipitation 
(see Materials and Methods) was 85% in FMDV-binding activity (which includes neutralizing and nonneutralizing antibodies) and 70% for FMDV- 
neutralizing activity. No detectable reactivity with FMDV or with peptides representing site A was found in the fraction not retained in protein A -  
Sepharose. The average yield of the A21-MBAH-Sepharose fractionation (see Materials and Methods) was 86% for FMDV-binding activity and 
87% for FMDV-neutralizing activity. Hence, no significant amount of anti-FMDV antibodies was lost during fractionation. 
bThe assignment of experiment and animal numbers is as in Table 2. Sera from animals VFAC-1 and VFAC-2 and also from animals 827-1,827- 
2, and 827-3 were provided as pooled sera; calculations with these sera were as indicated in footnote b of Table 2. 
CThe total immunoglobulin (Ig) concentration in serum was estimated from the amount of Ig purified by protein A-Sepharose chromatography, 
assuming 100% recovery (see also footnote a). 
~lg (%) is the percentage distribution of the total weight of Ig between the fraction not retained (NR) and the fraction retained (R) in the peptide 
A21 -MBAH-Sepharose. 
e Distribution (%) of the FMDV C-S8cl binding activity between antibodies not retained (NR) and retained (R) in A21 -MBAH-Sepharose. One unit 
of binding activity is defined as the amount of Ig needed to give a reference signal in the enzyme immunodot assay described under Materials 
and Methods. For each serum, and the fractions derived from it, the corresponding activities were obtained in the same experiment, using 
nensaturating amounts of antibody, as described under Materials and Methods. As a negative control, the fractionation procedure was applied to 
sera from nonimmunized pigs, and no detectable virus-binding activity was noted (results not shown). However, about 5% of the Ig purified from 
n0nimrnune sera bound unspecifically to A21 -MBAH-Sepharose and was not eluted either with 2 M KCI or with 0.1 M citrate, pH 4; it could be 
aluted with 0.1 M glycine-HCI, pH 2.5, but, as expected, it showed no reactivity with FMDV or with peptides A19 or A21. Thus, about 5% of the 
unspecific Ig, and also of the anti-FMDV antibodies not directed to site A, may contaminate site A-specific antibodies retained in the A21 -MBAH-  
8epharose. This modest amount of unspecific antibodies does not affect our conclusions, but it has been taken into consideration in the quantifica- 
ti0ns; the corrected values for the percentage distribution between fractions NR and R are given in parentheses. Unspecific Ig could be depleted 
from serum by passage through a MBAH-Sepharose resin whose reactive groups were blocked with 2-mercaptoethanol (data not shown). Only 
the R fraction reacted with peptides A21 or A19 in an immunodot assay, as expected (data not shown). 
~Distribution (%) of the O-S8cl-neutralizing activity between antibodies not retained (NR) and retained (R) in A21-MBAH-Sepharose. One unit 
of activity is defined as the amount of Ig needed to neutralize 50% of the plaques in the plaque-reduction assay described under Materiels and 
Methods. For each serum and fractions derived from it, the neutralizing activities were obtained in parallel, duplicate platings. Corrected values 
(0alculated as indicated in footnote e) are given in parentheses. 
~The N ratio is the ratio between the amount of Ig needed to neutralize 50% of the plaque-forming units of MAR mutant SD6-28 and C-S8cl in 
the plaque-reduction assay described under Materials and Methods. This ratio is given only for the antibody fraction retained in A21-MBAH-  
Sepharose (see text). Most of the residual virus-binding and neutralizing activities in the R fractions from sera of animals 39, 49, 53, and 64 were 
due to unspecific binding of antibodies not directed to site A (see footnote e). N values for these four sera have been excluded in the calculation 
of the average N value. ND, not determined. 
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FIG. 1. Analysis of antibodies from a swine vaccinated with FMDV. 
(A) Reactivity of tg fractions in an immunodot assay; the antigens ap- 
plied were, PBS (no antigen added); KLH, keyhole limpet haemocyanin 
(1.8 /~g); C-$8, purified FMDV C-S8cl (2, 20, amounts equivalent to 2 
and 20 pmol, respectively, of site A); A21, A19 indicate the correspond- 
ing synthetic peptides (20 pmol of peptide conjugated to less than 1.5 
#g of KLH) listed in Table 1. The antibodies used in the assay are 
indicated by the numbers on the top line as follows= 1, no first antibody 
added; 2, unfractionated serum (150 #g Ig) from an animal vaccinated 
with FMDV (experiment 7, animal 13; see Table 2); 3, total Ig from 
serum 13 retained in protein A-Sepharose (150 #g); 4, Ig from serum 
13 not retained in the A21-MBAH-Sepharose (135 #g); 5, Ig from 
serum 13 retained in the A21-MBAH-Sepharose (30 #g); 6, MAb SD6 
(about 10 #g) (described in 23). (B, C, D) Plaque-reduction neutralization 
assays using either FMDV 0-S8cl (filled symbols) or MAR mutant SD6- 
28 (open symbols) and serum or Ig fractions from animal 13. Neutraliza- 
tion by: (B) whole serum (circles) or purified total Ig (triangles); (C) Ig 
fraction not retained in A21 -MBAH-Sepharose; (D) Ig fraction retained 
in A21-MBAH-Sepharose; each value was obtained in duplicate; the 
average deviation from the mean was 5% of the mean. 
Lea et al., 1994). Perhaps because of such flexibility the 
interaction of site A with antibodies can be faithfully mim- 
icked with synthetic peptides. Antibodies directed to site 
A bind to intact virions to a similar extent as to synthetic 
peptides (considering equivalent molar amounts of pep- 
tide and of G-H loop segment in the virus; Mateu et aL, 
1989, 1992, and unpublished results). This has allowed 
quantitative fractionation by affinity chromatography. 
In our analyses we cannot completely exclude that a 
number of antibodies which did not bind to A21-AH-  
Sepharose could nevertheless recognize discontinuous 
epitopes involving the G-H loop of VP1. Even if this were 
the case, our evaluation of the G-H loop as a continuous 
antigenic domain would not be modified, although the 
results would underestimate the contribution of site A to 
the immune response. It must be noted, however, that 
peptides representing site A did not inhibit the binding 
to FMDV C-$8cl of the antibody fraction not retained in 
the A21-MBAH-Sepharose in competition ELISA 
assays (data not shown), an observation that renders 
unlikely that any significant proportion of site A-specific 
antibodies present in swine sera were unable to bind to 
the peptideA21 column. In contrast, peptides represent- 
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FIG. 2. Analysis of antibodies from a swine vaccinated with peptide 
p38. (A) Reactivity of Ig fractions in an immunodot assay; the antigens 
applied were, PBS (no antigen added); KLH, keyhole limpet hemocyanin 
(3 #g); C-$8, purified FMDV C-$8cl (2, 20: amounts equivalent o 2 and 
20 pmol, respectively, of site A); A21, A19, 018, and p38 indicate the 
corresponding synthetic peptides (20 pmol of peptide conjugated to 
less than 3 #g of KLH) listed in Table 1. The antibodies used in the 
assay are indicated by the numbers on the top line as follows= 1, no 
first antibody added; 2, serum from a nonimmunized pig (1,200 dilution); 
3, unfractionated serum from animal 51 (Table 2) (1,200 dilution, or 
about 90 fig Ig); 4, fraction from serum 51 not retained in protein A- 
Sepharose (90 #g); 5, Ig from serum 51 retained in protein A-Sepha- 
rose (90/~g); 6, Ig from serum 51 not retained in A21-MBAH-Sepha- 
rose (82 #g); 7, Ig from serum 51 retained in A21-MBAH-Sepharose 
(19 #g); 8, MAb 4G3 (about 30 #g) (described in 23). (B, 0, D) Plaque- 
reduction neutralization assays using either FMDV C-S8cl (filled sym- 
bols) or MAR mutant SD6-28 (open symbols) and serum or Ig fractions 
from animal 51. Neutralization by (B) whole serum (circles) or purified 
total Ig (triangles); (0) lg fraction not retained in A21-MBAH-Sepha- 
rose; (D) Ig fraction retained in A21-MBAH-Sepharose. Each value 
was obtained in duplicate; the average deviation from the mean was 
6% of the mean. 
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ing site A did inhibit in similar assays the binding of 
antibodies directed to discontinuous epitopes which in- 
volve site A of a FMDV of serotype O (Parry eta/. ,  1989). 
Also, the antigenically critical substitution H-146 ~ R in 
VP1 did not affect neutralization by antibodies not re- 
tained in the column (see Results and Table 3). Although 
the proportion of antibodies directed to a specific capsid 
site may vary for different animal species, virus serotypes 
0rvariants, vaccine formulations and immunization proto- 
cols, our conclusions are not inconsistent with experi- 
ments with FMDV of serotype O suggesting that more 
than 50% of the neutralizing activity from convalescent 
0rvaccinated bovine sera was directed to site A (quoted 
in Brown, 1990). However, a high proportion of the FMDV 
neutralizing antibodies in swine was elicited against 
sites different from site A (Table 3). 
The fraction of antibodies directed to site A varied 
greatly among individual swine, even in the same infec- 
tion or vaccination experiment (Tables 2 and 3). Thus it 
cannot be argued that altered antigens were adminis- 
tered to some animals. A significant proportion of host 
individuals failed to respond efficiently to site A. Thus, 
during its natural spread, FMDV may encounter host ani- 
mals that generate (or have previously generated) a 
strong site A-specific immune response, and other indi- 
viduals in which such a response is weak or nonexistent. 
Such heterogeneous dominance may account for the sur- 
prisingly low proportion of natural type C isolates [C~ 
Haute Loire Fr/69, 05 Argentina/69, C Philippines and 
some isolates from a recent outbreak in Argentina (Ma- 
teu et al., 1988; Martinez et a/., 1991; Feigelstock et a/., 
unpublished results)] harboring antigenically drastic 
amino acid replacements within site A. Recently, we have 
shown that FMDV 0-$8cl  subjected to continuous anti- 
body pressure directed to site A accumulates amino acid 
substitutions at the cost of viral fitness (Borrego et a/., 
1993). If such a fitness decrease occurred also in swine, 
occasional replication of FMDV in animals deficient in 
antibodies directed to site A may allow fitness recovery 
and the maintenance of low mutant frequencies around 
the region encoding the conserved RGD triplet. It is inter- 
esting that immunological "blindspots" in some individu- 
als not only may permit replication of certain mutant 
types in viral quasispecies (Holland eta/. ,  1982) but may 
als0 relieve a detrimental selection pressure in viruses 
such as FMDV with an icosahedral capsid which proba- 
blydisplay a limited tolerance to amino acid substitutions 
(Martlnez et aL, 1992; Borrego et al., 1993; Lea et al., 
1994; Mateu et a/., 1994; Takeda et a/., 1994). 
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